Krauspenhaar R, Eschenburg S, Perbandt M, Kornilov V, Konareva N, Mikailova I, Stoeva S, Wacker R, Maier T, Singh T, Mikhailov A, Voelter W, Betzel C
Institute of Physiological Chemistry, University Hospital, c/o DESY, Build. 22a, Notkestrasse 85, Hamburg, 22603, Germany.
Biochem Biophys Res Commun. 1999 Apr 13;257(2):418-24. doi: 10.1006/bbrc.1999.0470.
The crystal structure of the ribosome-inactivating protein (RIP) mistletoe lectin I (ML-I) from Viscum album has been solved by molecular replacement techniques. The structure has been refined to a crystallographic R-factor of 24.5% using X-ray diffraction data to 2.8 A resolution. The heterodimeric 63-kDa protein consists of a toxic A subunit which exhibits RNA-glycosidase activity and a galactose-specific lectin B subunit. The overall protein fold is similar to that of ricin from Ricinus communis; however, unlike ricin, ML-I is already medically applied as a component of a commercially available misteltoe extract with immunostimulating potency and for the treatment of human cancer. The three-dimensional structure reported here revealed structural details of this pharmaceutically important protein. The comparison to the structure of ricin gives more insights into the functional mechanism of this protein, provides structural details for further protein engineering studies, and may lead to the development of more effective therapeutic RIPs.
已通过分子置换技术解析了来自欧洲槲寄生的核糖体失活蛋白(RIP)槲寄生凝集素I(ML-I)的晶体结构。利用分辨率为2.8 Å的X射线衍射数据,该结构已精修至晶体学R因子为24.5%。这种63 kDa的异二聚体蛋白由具有RNA糖苷酶活性的毒性A亚基和半乳糖特异性凝集素B亚基组成。蛋白质的整体折叠结构与蓖麻毒素相似;然而,与蓖麻毒素不同的是,ML-I已作为一种具有免疫刺激效力且可用于治疗人类癌症的市售槲寄生提取物的成分在医学上得到应用。此处报道的三维结构揭示了这种具有药学重要性的蛋白质的结构细节。与蓖麻毒素结构的比较为该蛋白质的功能机制提供了更多见解,为进一步的蛋白质工程研究提供了结构细节,并可能有助于开发更有效的治疗性RIP。